Oliver Sartor, M.D.
Dr. Sartor received his MD from Tulane University with honors in 1982. After internship at the University of Pennsylvania, he trained in Internal Medicine at Tulane Medical School. After completing fellowship at the National Cancer Institute (NCI) in Bethesda, Maryland in 1989, he served until 1993 as a Senior Investigator at the NCI and began focusing on novel therapeutics for advanced prostate cancer patients.
Dr. Sartor returned to Louisiana in 1993 to serve as an Associate Professor at the LSU Medical School in Shreveport and then moved to the LSU Health Sciences Center in New Orleans in 1998 as the Patricia Powers Strong Professor of Oncology, Stanley S. Scott Cancer Center Director, and Hematology/Oncology Section Chief.
Dr. Sartor was the Co-Director of the Louisiana Cancer Research Consortium, starting at its legislative inception in 2002. In March 2006, he left LSU to join the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute and the Harvard Medical School.
In January 2008, Dr. Sartor joined Tulane University as the C. E. and Bernadine Laborde Professor of Cancer Research in the Departments of Medicine and Urology. In July 2010, Dr. Sartor was named Medical Director of the Tulane Cancer Center.
Dr. Sartor’s interests have focused broadly on prostate cancer, predominantly in those patients who failed initial therapies. His publications range from genetic studies on prostate cancer to clinical trials involving novel agents. He has been a lead author on two studies pivotal for FDA drug approval in prostate cancer and has been the PI or co-PI on a number of prospective international clinical trials evaluating new therapies for patients with advanced prostate cancer.
Dr. Sartor has published over 100 scholarly articles, is the Medical Oncology Co-Chair of the Radiation Therapy Oncology Group (RTOG) Genitourinary Committee, is the Co-Editor in Chief of the peer-reviewed journal “Clinical Genitourinary Cancer”, and serves as Chairman of the Department of Defense Prostate Cancer Integration Panel in 2008-2009.
Tulane Cancer Center
Dr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a fellowship at the National Cancer Institute (NCI). He has published over 300 articles and book chapters and led multiple national and international clinical trials as either a principal investigator or co-principal investigator. In particular he has helped to lead pivotal trials leading to FDA approval for samarium-153 EDTMP, radium-223, and cabazitaxel. He has lectured widely, and at last count has given invited lectures in 28 countries.
He is currently the Assistant Dean for Oncology at Tulane University School of Medicine, Medical Director of the Tulane Cancer Center and the Laborde Professor for Cancer Research, with appointments in both the Medicine and Urology Departments.
He has served as the past Chairman of the Department of Defense Prostate Cancer Integration Panel, is currently Editor-in-Chief of the peer-reviewed journal Clinical Genitourinary Cancer, and is the Medical Oncology Chair of the GU committee of NRG. He is also currently a member of the NCI Board of Scientific Counselors (Clinical Sciences and Epidemiology).
Publications & Presentations
Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wootten A, Walsh PC, Costello AJ. The Melbourne Consensus Statement on the Early Detection of Prostate Cancer.BJU Int. 2013 Nov 8. doi: 10.1111/bju.12556. [Epub ahead of print] No abstract available.
Parker C, Sartor O. Radium-223 in prostate cancer. N Engl J Med. 2013 Oct 24;369(17):1659-60. doi: 10.1056/NEJMc1310231. No abstract available.
Egan A, Dong Y, Zhang H, Qi Y, Balk SP, Sartor O. Castration-resistant prostate cancer: Adaptive responses in the androgen axis. Cancer Treat Rev. 2013 Sep 14. pii: S0305-7372(13)00200-4. doi: 10.1016/j.ctrv.2013.09.011. [Epub ahead of print]
Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, Sternberg CN, Shen L, Oudard S, de Bono J, Sartor O. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013 Nov 20;105(22):1729-37. doi: 10.1093/jnci/djt280. Epub 2013 Oct 17.
Halabi S, Armstrong AJ, Sartor O, de Bono J, Kaplan E, Lin CY, Solomon NC, Small EJ. Prostate-specific antigen changes as surrogate for overall survival in men with etastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol. 2013 Nov 1;31(31):3944-50. doi: 10.1200/JCO.2013.50.3201. Epub 2013 Oct 7.
Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol. 2014 Feb;65(2):289-99. doi: 10.1016/j.eururo.2013.08.008. Epub 2013 Aug 11.
Sartor AO. Surveillance for prostate cancer: are the proceduralists running amok? Oncology (Williston Park). 2013 Jun;27(6):523, 593. No abstract available.
Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall’Oglio M, Franzén L, Coleman R, Vogelzang NJ, O’Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O, ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.
Valicenti RK, Thompson I Jr, Albertsen P, Davis BJ, Goldenberg SL, Wolf JS, Sartor O, Klein E, Hahn C, Michalski J, Roach M 3rd, Faraday MM. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. American Society for Radiation Oncology/American Urological Association. Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):822-8. doi: 10.1016/j.ijrobp.2013.05.029. Review.
WHAT PATIENTS ARE SAYING...
Dr. Spencer Krane
New intake with Dr. Spencer Krane went great! He took the time to listen to me and come up with a plan that makes sense. It's nice when you find a physician that fits. Thanks!
Advanced Prostate Cancer Can Be Successfully Treated
Men with advanced prostate cancer can be treated with androgen derivation therapy. ADT reduces the testosterone level which often serves as fuel for prostate cancer cells.